FDA ADVISORY COMMITTEE MEETING APRIL 12, 2007 BACKGROUND INFORMATION PACKAGE CAPRION PHARMACEUTICALS INC. - AB5 toxins - Document - PDFSEARCH.IO

First Page	Meta Content
	FDA ADVISORY COMMITTEE MEETING APRIL 12, 2007 BACKGROUND INFORMATION PACKAGE CAPRION PHARMACEUTICALS INC. Add to Reading List Document Date: 2007-04-10 08:13:09 Open Document File Size: 410,43 KB Share Result on Facebook City Montreal / / Company Fleming / Caprion Pharmaceuticals Inc. / Gram Gb3 Glycolipid Globotriaosylceramide GI Gastrointestinal GRP Group / / Country Canada / / Facility The Stx-Gb3 complex / / IndustryTerm TREATMENT OF SHIGA TOXIN-MEDIATED DISEASE / / MedicalCondition glucose intolerance / proteinuria / abdominal pain / E. coli O157 / Organization FDA US Food and Drug Administration / AE DMID Division of Microbiology / FDA / FDA Advisory Committee / NIH National Institute of Health / Centers for Disease Control and Prevention / / Position treating physician / Major / / Product Sorbitol / / ProvinceOrState Quebec / / Technology Alpha / ANTIBODIES / apoptosis / / SocialTag Enterobacteria Gram-negative bacteria Gut flora AB5 toxins Shiga toxin Escherichia coli O157:H7 Verotoxin-producing Escherichia coli Hemolytic-uremic syndrome Enterohemorrhagic Bacteria

FDA ADVISORY COMMITTEE MEETING APRIL 12, 2007 BACKGROUND INFORMATION PACKAGE CAPRION PHARMACEUTICALS INC.Add to Reading List